DOV 216,303 is an experimental antidepressant drug originally developed by DOV Pharmaceutical and was licensed to Merck & Co. in 2004;[1] Merck and DOV terminated their relationship in December 2006.

[2]: 12 [3] It is a triple reuptake inhibitor (TRI), or serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI).

[4] It is the racemic mixture of amitifadine (DOV-21,947) and its (–)-enantiomer, DOV-102,677.

[4] As of March 2008, DOV had no intention to further develop DOV-216,303 because the patent on the compound had expired.

[2]: 6 In a mouse model, DOV-216,303 has shown the ability to promote recovery after spinal cord contusion.